---
title: 'Predictors of early morbidity and mortality in newly diagnosed multiple myeloma:
  data from five randomized, controlled, phase III trials in 3700 patients'
date: '2023-12-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38062124/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231208170741&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Early morbidity and mortality affect patient outcomes in multiple myeloma.
  Thus, we dissected the incidence and causes of morbidity/mortality during induction
  therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed/validated
  a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated
  in 2005-2020 with novel agent-based triplet/quadruplet IT. Primary endpoints were
  severe infections, death, or a combination of both. Patients were divided in a training
  (n ...
disable_comments: true
---
Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed/validated a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated in 2005-2020 with novel agent-based triplet/quadruplet IT. Primary endpoints were severe infections, death, or a combination of both. Patients were divided in a training (n ...